Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(13 sites)
United States
University of Chicago, Chicago, Illinois Northwestern University, Evanston, Illinois Brown University Health, Providence, Rhode Island Sarah Cannon Research Institute, Nashville, Tennessee MD Anderson Cancer Center, Houston, Texas Germany
Universitätsklinikum Ulm, Ulm, Baden-Wurttemberg Universitätsklinikum Erlangen, Erlangen, Bavaria Klinikum der Universität München, Munich, Bavaria Universitätsklinikum Marburg, Marburg, Hesse Uniklinikum Erlangen, Essen, North Rhine-Westphalia Universitätsklinikum Dresden, Dresden, Saxony Charité Universitätsmedizin Berlin, Berlin Universitätsklinikum Hamburg-Eppendorf, Hamburg